However, a recent study reported that low doses of metformin, DPP4 inhibitors, GLP1 analogs, and especially SGLT2 inhibitors were associated with lower odds of depression than non-users of these medications [20]. This evidence concerns the gene SLC5A2 and major depressive disorder.